Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)
 
 • Company Description   
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

Number of Employees: 143

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.98 Daily Weekly Monthly
20 Day Moving Average: 696,007 shares
Shares Outstanding: 81.59 (millions)
Market Capitalization: $1,140.66 (millions)
Beta: 0.39
52 Week High: $27.20
52 Week Low: $9.90
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.07% -4.27%
12 Week 18.68% -3.18%
Year To Date -27.07% -30.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
221 CRESCENT STREET SUITE 103A
-
WALTHAM,MA 02453
USA
ph: 617-272-4600
fax: 760-537-4101
ir@viridiantherapeutics.com http://www.viridiantherapeutics.com
 
 • General Corporate Information   
Officers
Stephen Mahoney - President; Chief Executive Officer and Director
Tomas Kiselak - Chairman
Seth Harmon - Chief Financial Officer
Sarah Gheuens - Director
Peter Harwin - Director

Peer Information
Viridian Therapeutics, Inc. (CORR.)
Viridian Therapeutics, Inc. (RSPI)
Viridian Therapeutics, Inc. (CGXP)
Viridian Therapeutics, Inc. (BGEN)
Viridian Therapeutics, Inc. (GTBP)
Viridian Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92790C104
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 81.59
Most Recent Split Date: 11.00 (0.07:1)
Beta: 0.39
Market Capitalization: $1,140.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.01 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.01 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.74
Price/Cash Flow: -
Price / Sales: 3,777.01
EPS Growth
vs. Year Ago Period: -10.13%
vs. Previous Quarter: -7.41%
Sales Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
ROE
06/30/25 - -
03/31/25 - -70.61
12/31/24 - -63.01
ROA
06/30/25 - -
03/31/25 - -44.67
12/31/24 - -39.55
Current Ratio
06/30/25 - -
03/31/25 - 19.49
12/31/24 - 15.43
Quick Ratio
06/30/25 - -
03/31/25 - 19.49
12/31/24 - 15.43
Operating Margin
06/30/25 - -
03/31/25 - -102,092.39
12/31/24 - -89,387.09
Net Margin
06/30/25 - -
03/31/25 - -102,092.39
12/31/24 - -89,387.09
Pre-Tax Margin
06/30/25 - -
03/31/25 - -102,092.39
12/31/24 - -89,387.09
Book Value
06/30/25 - -
03/31/25 - 5.09
12/31/24 - 6.09
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.05
12/31/24 - 0.04
Debt-to-Capital
06/30/25 - -
03/31/25 - 3.31
12/31/24 - 2.97
 

Powered by Zacks Investment Research ©